Novartis seeks new Gleevec indication

Novartis (NVS; SWX:NOVN) submitted an sNDA to the FDA for its Gleevec imatinib mesylate to treat unresectable and metastatic malignant gastrointestinal stromal tumors (GISTs). Gleevec is approved to t...